Home Healthcare Pharmaceuticals IV and Oral Iron Drugs Market

IV and Oral Iron Drugs Market Size, Share & Trends Analysis Report By Drug Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Ferric Gluconate, Others), By Route of Administration (IV, Oral), By Application (Chronic Kidney Diseases, Inflammatory Bowel Diseases, Oncology-induced Anemia, Iron Deficiency Anemia, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 13, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. IV and Oral Iron Drugs Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Iron Dextran
    2. Iron Sucrose
    3. Ferric Carboxymaltose
    4. Ferric Gluconate
    5. Others
  2. IV and Oral Iron Drugs Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. IV
    2. Oral
  3. IV and Oral Iron Drugs Market, By Application  2022-2034 (USD MILLION/ Units)
    1. Chronic Kidney Diseases
    2. Inflammatory Bowel Diseases
    3. Oncology-induced Anemia
    4. Iron Deficiency Anemia
    5. Others
  4. Regional IV and Oral Iron Drugs Market
    1. North America
      1. North America IV and Oral Iron Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
      2. North America IV and Oral Iron Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. IV
        2. Oral
      3. North America IV and Oral Iron Drugs Market By Application  2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Diseases
        2. Inflammatory Bowel Diseases
        3. Oncology-induced Anemia
        4. Iron Deficiency Anemia
        5. Others
      4. U.S.
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      5. Canada
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
    2. Europe
      1. Europe IV and Oral Iron Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
      2. Europe IV and Oral Iron Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. IV
        2. Oral
      3. Europe IV and Oral Iron Drugs Market By Application  2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Diseases
        2. Inflammatory Bowel Diseases
        3. Oncology-induced Anemia
        4. Iron Deficiency Anemia
        5. Others
      4. U.K.
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      5. Germany
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      6. France
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      7. Spain
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      8. Italy
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      9. Russia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      10. Nordic
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      11. Benelux
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      12. Rest of Europe
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
    3. APAC
      1. APAC IV and Oral Iron Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
      2. APAC IV and Oral Iron Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. IV
        2. Oral
      3. APAC IV and Oral Iron Drugs Market By Application  2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Diseases
        2. Inflammatory Bowel Diseases
        3. Oncology-induced Anemia
        4. Iron Deficiency Anemia
        5. Others
      4. China
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      5. Korea
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      6. Japan
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      7. India
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      8. Australia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      9. Singapore
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      10. Taiwan
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      11. South East Asia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      12. Rest of Asia-Pacific
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
    4. Middle East and Africa
      1. Middle East and Africa IV and Oral Iron Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
      2. Middle East and Africa IV and Oral Iron Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. IV
        2. Oral
      3. Middle East and Africa IV and Oral Iron Drugs Market By Application  2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Diseases
        2. Inflammatory Bowel Diseases
        3. Oncology-induced Anemia
        4. Iron Deficiency Anemia
        5. Others
      4. UAE
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      5. Turkey
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      6. Saudi Arabia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      7. South Africa
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      8. Egypt
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      9. Nigeria
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      10. Rest of MEA
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
    5. LATAM
      1. LATAM IV and Oral Iron Drugs Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
      2. LATAM IV and Oral Iron Drugs Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. IV
        2. Oral
      3. LATAM IV and Oral Iron Drugs Market By Application  2022-2034 (USD MILLION/ Units)
        1. Chronic Kidney Diseases
        2. Inflammatory Bowel Diseases
        3. Oncology-induced Anemia
        4. Iron Deficiency Anemia
        5. Others
      4. Brazil
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      5. Mexico
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      6. Argentina
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      7. Chile
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      8. Colombia
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
      9. Rest of LATAM
        1. Iron Dextran
        2. Iron Sucrose
        3. Ferric Carboxymaltose
        4. Ferric Gluconate
        5. Others
        6. IV
        7. Oral
        8. Chronic Kidney Diseases
        9. Inflammatory Bowel Diseases
        10. Oncology-induced Anemia
        11. Iron Deficiency Anemia
        12. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.